Published in Blood on August 23, 2010
How I treat acquired aplastic anemia. Blood (2012) 2.44
Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev (2013) 1.12
The complex pathophysiology of acquired aplastic anaemia. Clin Exp Immunol (2015) 0.91
Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. Medicine (Baltimore) (2013) 0.85
Highly skewed T-cell receptor V-beta chain repertoire in the bone marrow is associated with response to immunosuppressive drug therapy in children with very severe aplastic anemia. Blood Cancer J (2011) 0.83
Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia. J Immunol (2016) 0.82
Intraperitoneal Injection of Multiplacentas Pooled Cells Treatment on a Mouse Model with Aplastic Anemia. Stem Cells Int (2016) 0.82
Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in COPD. Respir Res (2011) 0.81
An unexpected role for platelets in blocking Th17 differentiation. J Clin Invest (2014) 0.80
Impaired immunomodulatory ability of bone marrow mesenchymal stem cells on CD4(+) T cells in aplastic anemia. Results Immunol (2012) 0.79
Abnormalities in Th17 T cells in aplastic anemia. Blood (2010) 0.78
CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemia. Blood (2015) 0.78
Rapamycin is highly effective in murine models of immune-mediated bone marrow failure. Haematologica (2017) 0.77
Immune-mediated bone marrow failure in C57BL/6 mice. Exp Hematol (2014) 0.77
Expression of IL-27, Th1 and Th17 in patients with aplastic anemia. J Clin Immunol (2012) 0.76
Reduced IL-33 plasma levels in aplastic anemia. Cancer Cell Int (2015) 0.75
NOTCH signaling in immune-mediated bone marrow failure of aplastic anemia. Rare Dis (2013) 0.75
Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. J Transl Med (2017) 0.75
In patients with chronic aplastic anemia, bone marrow-derived MSCs regulate the Treg/Th17 balance by influencing the Notch/RBP-J/FOXP3/RORγt pathway. Sci Rep (2017) 0.75
Mechanism of immunosuppressants combined with cord blood for severe aplastic anemia. Int J Clin Exp Med (2015) 0.75
Bullous Pemphigoid Accompanied by Aplastic Anemia: The Induction of IL-17-Producing Cells in the Affected Areas of the Skin. Case Rep Dermatol (2012) 0.75
Somatic HLA Mutations Expose the Role of Class I-Mediated Autoimmunity in Aplastic Anemia and its Clonal Complications. Blood Adv (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
Interleukin-17 family members and inflammation. Immunity (2004) 16.16
Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol (2007) 13.70
Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol (2007) 12.76
T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol (2007) 12.20
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest (2006) 11.89
Phenotypic and functional features of human Th17 cells. J Exp Med (2007) 11.33
IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol (2007) 10.71
Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 10.26
Interleukin-17 and type 17 helper T cells. N Engl J Med (2009) 6.83
Regulation of inflammatory responses by IL-17F. J Exp Med (2008) 5.56
Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med (2008) 5.25
Th17 cells in human disease. Immunol Rev (2008) 4.27
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol (2005) 3.42
Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol (2008) 3.11
In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet (2004) 2.47
Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med (1991) 2.40
Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol (2005) 2.26
Aplastic anemia. Curr Opin Hematol (2008) 2.17
IL-17 contributes to CD4-mediated graft-versus-host disease. Blood (2008) 2.07
The pathophysiology of acquired aplastic anemia. N Engl J Med (1997) 2.05
Type 17 CD8+ T cells display enhanced antitumor immunity. Blood (2009) 2.02
FOXP3 acts as a rheostat of the immune response. Immunol Rev (2005) 1.86
Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol (2009) 1.73
T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood (2006) 1.64
IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells. J Exp Med (2008) 1.58
Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood (2007) 1.44
A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol (2004) 1.42
Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J (1970) 1.32
Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol (2009) 1.30
IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol (2009) 1.30
Interplay between effector Th17 and regulatory T cells. J Clin Immunol (2008) 1.29
Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J Immunol (2007) 1.28
Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy. Blood (2010) 1.27
Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood (2004) 1.12
The role of the Th1 transcription factor T-bet in a mouse model of immune-mediated bone-marrow failure. Blood (2009) 0.95
Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. Br J Haematol (2004) 0.94
Cytokine gene polymorphisms in acquired bone marrow failure. Am J Hematol (2007) 0.91
Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. Br J Haematol (2008) 0.90
The IL-17 cytokine family members are inhibitors of human hematopoietic progenitor proliferation. Blood (2006) 0.87
Gamma interferon and aplastic anemia. Blood (1987) 0.81
Characteristics and clinical relevance of autolymphocytotoxins in patients with aplastic anemia. Transplantation (1986) 0.80
Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med (2005) 7.09
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Telomere diseases. N Engl J Med (2009) 5.68
Augmented Wnt signaling in a mammalian model of accelerated aging. Science (2007) 5.62
Current concepts in the pathophysiology and treatment of aplastic anemia. Blood (2006) 5.20
Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood (2008) 4.34
Hematopoietic-specific microRNA expression in human cells. Leuk Res (2005) 3.95
Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med (2012) 3.93
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA (2003) 3.90
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med (2011) 3.82
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing. Proc Natl Acad Sci U S A (2013) 3.35
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol (2007) 3.18
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood (2012) 2.88
Effect of soybean protein on blood pressure: a randomized, controlled trial. Ann Intern Med (2005) 2.79
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet (2003) 2.76
Ankle-brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis. Am J Epidemiol (2005) 2.75
Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood (2003) 2.73
Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet (2009) 2.73
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood (2006) 2.69
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood (2012) 2.51
In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet (2004) 2.47
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood (2011) 2.47
How I treat acquired aplastic anemia. Blood (2012) 2.44
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 2.44
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2013) 2.29
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood (2006) 2.21
Aplastic anemia. Curr Opin Hematol (2008) 2.17
Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet (2012) 2.17
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation (2005) 2.13
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood (2009) 2.12
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood (2002) 2.10
Telomere maintenance and human bone marrow failure. Blood (2008) 2.09
Psychosocial factors and coronary calcium in adults without clinical cardiovascular disease. Ann Intern Med (2006) 2.06
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res (2013) 2.00
Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood (2004) 1.99
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood (2013) 1.97
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood (2008) 1.95
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol (2006) 1.88
Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood (2004) 1.83
Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol (2006) 1.82
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol (2010) 1.79
Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology (2011) 1.77
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica (2009) 1.73
Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood (2004) 1.70
TCR beta-chain sharing in human CD8+ T cell responses to cytomegalovirus and EBV. J Immunol (2008) 1.70
Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol (2006) 1.68
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma (2011) 1.68
Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J Immunother (2006) 1.65
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res (2012) 1.65
T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood (2006) 1.64
Prevalence of physical activity among Chinese adults: results from the International Collaborative Study of Cardiovascular Disease in Asia. Am J Public Health (2005) 1.63
Mutations in the SBDS gene in acquired aplastic anemia. Blood (2007) 1.62
Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol (2003) 1.59
Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood (2006) 1.57
A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One (2009) 1.57
Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care (2007) 1.53
Cytoplasmic reactive oxygen species and SOD1 regulate bone mass during mechanical unloading. J Bone Miner Res (2013) 1.51
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol (2008) 1.49
Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog (2012) 1.49
Blood pressure response to potassium supplementation is associated with genetic variation in endothelin 1 and interactions with E selectin in rural Chinese. J Hypertens (2010) 1.47
Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood (2004) 1.46
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood (2007) 1.44
A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol (2004) 1.42
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Leuk Lymphoma (2014) 1.41
Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol (2008) 1.41
Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol (2004) 1.40
Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J Virol (2007) 1.40